Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
23.06
-0.22 (-0.95%)
Jan 21, 2026, 1:35 PM HKT
HKG:1877 Revenue
Shanghai Junshi Biosciences had revenue of 637.50M CNY in the quarter ending September 30, 2025, with 31.40% growth. This brings the company's revenue in the last twelve months to 2.48B, up 38.93% year-over-year. In the year 2024, Shanghai Junshi Biosciences had annual revenue of 1.95B with 29.67% growth.
Revenue (ttm)
2.48B CNY
Revenue Growth
+38.93%
P/S Ratio
13.39
Revenue / Employee
963.15K CNY
Employees
2,578
Market Cap
36.33B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
| Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
| Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
| Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
| Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 9.94B |
| Genscript Biotech | 6.50B |
| Shanghai Henlius Biotech | 6.35B |
| Zai Lab | 3.44B |
| RemeGen | 2.43B |
| Duality Biotherapeutics | 2.38B |
| InnoCare Pharma | 1.56B |
| Biocytogen Pharmaceuticals (Beijing) | 1.30B |